Durability of the First Biologic in Children and Adults With Ulcerative Colitis : A Nationwide Study from the epi-IIRN
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: In this nationwide study, our objective was to compare the durability of first-line biologics in ulcerative colitis (UC), categorized into monotherapy and combotherapy with immunomodulators.
METHODS: We utilized data from the nationwide epi-IIRN cohort from 2005 to 2020. Durability was defined as consistent treatment without surgery. Comparisons were based on stringent propensity score-matching.
RESULTS: We included 15 111 patients with UC, of whom 2322 (15%) received biologics, with a median follow-up of 7.0 years (interquartile range, 3.8-11.0). The durability rate was similar between pediatric-onset and adults after 1 and 5 years from initiation of treatment (72% and 43% vs 71% and 43%, respectively; P = .8). Durability of adalimumab vs infliximab after 1 or 5 years was similar, whether prescribed as monotherapy (65%/46% vs 63%/33%, respectively; n = 182 matched pairs, P = .3) or combotherapy (78%/56% vs 91%/58%, respectively; n = 46 matched pairs, P = .4). Durability of infliximab was higher as combotherapy (85%/50%) vs monotherapy (69%/42%; n = 174 matched pairs, P = .007), while it was similar for adalimumab (80%/52% vs 74%/52%; n = 53 matched pairs, P = .4). The durability rate was similar for vedolizumab monotherapy (77%/56%) compared with adalimumab monotherapy (69%/52%; n = 125 matched patients, P = .1), and infliximab monotherapy (73%/55% vs 62%/44%; n = 78 matched patients, P = .1). However, combotherapy of antitumor necrosis factors (TNFs) had longer durability than vedolizumab (85%/50% vs 75%/43%, respectively; n = 131 matched pairs, P = .02).
CONCLUSION: After 5 years of treatment, 43% of the patients with UC sustained their first biologic, with similar durability in pediatric and adult-onset onset disease. Anti-TNFs had similar durability to vedolizumab and superior durability when prescribed as combotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - (2024) vom: 05. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atia, Ohad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/ibd/izae067 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370683390 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370683390 | ||
| 003 | DE-627 | ||
| 005 | 20240406232716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ibd/izae067 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370683390 | ||
| 035 | |a (NLM)38578929 | ||
| 035 | |a (PII)izae067 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atia, Ohad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durability of the First Biologic in Children and Adults With Ulcerative Colitis |b A Nationwide Study from the epi-IIRN |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: In this nationwide study, our objective was to compare the durability of first-line biologics in ulcerative colitis (UC), categorized into monotherapy and combotherapy with immunomodulators | ||
| 520 | |a METHODS: We utilized data from the nationwide epi-IIRN cohort from 2005 to 2020. Durability was defined as consistent treatment without surgery. Comparisons were based on stringent propensity score-matching | ||
| 520 | |a RESULTS: We included 15 111 patients with UC, of whom 2322 (15%) received biologics, with a median follow-up of 7.0 years (interquartile range, 3.8-11.0). The durability rate was similar between pediatric-onset and adults after 1 and 5 years from initiation of treatment (72% and 43% vs 71% and 43%, respectively; P = .8). Durability of adalimumab vs infliximab after 1 or 5 years was similar, whether prescribed as monotherapy (65%/46% vs 63%/33%, respectively; n = 182 matched pairs, P = .3) or combotherapy (78%/56% vs 91%/58%, respectively; n = 46 matched pairs, P = .4). Durability of infliximab was higher as combotherapy (85%/50%) vs monotherapy (69%/42%; n = 174 matched pairs, P = .007), while it was similar for adalimumab (80%/52% vs 74%/52%; n = 53 matched pairs, P = .4). The durability rate was similar for vedolizumab monotherapy (77%/56%) compared with adalimumab monotherapy (69%/52%; n = 125 matched patients, P = .1), and infliximab monotherapy (73%/55% vs 62%/44%; n = 78 matched patients, P = .1). However, combotherapy of antitumor necrosis factors (TNFs) had longer durability than vedolizumab (85%/50% vs 75%/43%, respectively; n = 131 matched pairs, P = .02) | ||
| 520 | |a CONCLUSION: After 5 years of treatment, 43% of the patients with UC sustained their first biologic, with similar durability in pediatric and adult-onset onset disease. Anti-TNFs had similar durability to vedolizumab and superior durability when prescribed as combotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adalimumab | |
| 650 | 4 | |a durability | |
| 650 | 4 | |a infliximab | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 4 | |a vedolizumab | |
| 700 | 1 | |a Friss, Chagit |e verfasserin |4 aut | |
| 700 | 1 | |a Focht, Gili |e verfasserin |4 aut | |
| 700 | 1 | |a Magen Rimon, Ramit |e verfasserin |4 aut | |
| 700 | 1 | |a Ledderman, Natan |e verfasserin |4 aut | |
| 700 | 1 | |a Greenfeld, Shira |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Tov, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Loewenberg Weisband, Yiska |e verfasserin |4 aut | |
| 700 | 1 | |a Matz, Eran |e verfasserin |4 aut | |
| 700 | 1 | |a Gorelik, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Chowers, Yehuda |e verfasserin |4 aut | |
| 700 | 1 | |a Dotan, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Dan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g (2024) vom: 05. Apr. |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izae067 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||